Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 10Unknown 8Recruiting 8Withdrawn 1Terminated 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 36Lymphoma, Large B-Cell, Diffuse 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 7Neoplasms 6Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6Leukemia 6Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Recurrence 3Neoplasm Metastasis 3Lymphoma, T-Cell 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Pain 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphatic Diseases 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Hematologic Diseases 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Sezary Syndrome 1

Interventions

Lenalidomide 5Rituximab 4Brentuximab Vedotin 4Vincristine 3Etoposide 3Cyclophosphamide 3romidepsin 2Vorinostat 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Doxorubicin 2Dasatinib 2tislelizumab 1selinexor 1plerixafor 1pembrolizumab 1pegfilgrastim 1parsaclisib 1obinutuzumab 1obatoclax 1monomethyl auristatin E 1liposomal doxorubicin 1ixazomib 1idelalisib 1ibrutinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1etoposide phosphate 1denileukin diftitox 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell, Peripheral × Prednisone × Clear all
NCT04548700 2024-03-07

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Terminated
38 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡